Cellectis Romainvil (CMVLF) 29.0000 $CMVLF
Not For The Faint Of CAR-T: The CAR-T Landscape In Early 2015
EP Vantage - Seeking Alpha - Fri Feb 06, 1:26PM CST
This is an extract from a longer report. If you followed last year's explosion of enthusiasm in CAR therapies you might have assumed that this was a super-novel approach that had just burst onto the scientific stage. In fact work on the synthetic...
BLUE: 90.70 (+0.93), CLRB: 2.45 (+0.28), BLCM: 20.00 (-0.81), KITE: 62.59 (+0.82), JUNO: 40.52 (+0.18), NVS: 102.20 (-0.17)
CAR-T Vs ErbB3 Market Opportunity Comparison
Decision Analytics - Seeking Alpha - Wed Jan 21, 12:32PM CST
CAR-T therapy, also known as "Adoptive Immunotherapy", has been the result of significant investor excitement recently. One look at the stock charts for JUNO and KITE is illustrative of this optimism. While this enthusiasm may be warranted,...
MACK: 10.22 (+0.40), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), BLCM: 20.00 (-0.81), KITE: 62.59 (+0.82), AVEO: 0.84 (-0.06), JUNO: 40.52 (+0.18), GSK: 47.94 (+1.99), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Kite Pharma/Amgen: A Strong Combination
Henry Wolfe - at Seeking Alpha - Thu Jan 15, 12:19PM CST
ZIOP: 9.64 (-0.35), BLCM: 20.00 (-0.81), KITE: 62.59 (+0.82), AMGN: 153.48 (+0.30), JUNO: 40.52 (+0.18)
Cellectis and Ohio State University, Through the Ohio State Innovation Foundation, Enter Into Licensing Agreement for Chimeric Antigen Receptor Technology Targeting Multiple Myeloma
Business Wire - Tue Jan 13, 12:30AM CST
Regulatory News:
Cellectis Plans to Conduct Registered Initial Public Offering in the U.S.
Business Wire - Thu Jan 08, 12:17PM CST
Regulatory News:
Cellectis Announces the Issuance by the USPTO of a Patent Covering a Seminal Nuclease-Based "gene editing" Method
Business Wire - Tue Jan 06, 11:30AM CST
Regulatory News:
Cellectis Is Late To The CAR-T Cell Race, But Could Finish First
Intrepid Investor - at Seeking Alpha - Fri Jan 02, 3:21PM CST
BLUE: 90.70 (+0.93), BLCM: 20.00 (-0.81), KITE: 62.59 (+0.82), JUNO: 40.52 (+0.18), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
Cellectis Plant Sciences and Two Blades Foundation Announce the Execution of a Cross-License Agreement on TAL Effector Nuclease Technologies
Business Wire - Thu Dec 18, 11:00AM CST
Regulatory News:
Cellectis Announces Upcoming Presentations at the 56th Annual Meeting of the American Society of Hematology (ASH)
Business Wire - Mon Nov 24, 11:19AM CST
Regulatory News :
Cellectis Received Proceeds of EUR13 Million Through the Exercise of Warrants
Business Wire - Wed Nov 12, 12:47PM CST
Regulatory News:
Cellectis: TALEN(TM) Technology: Grant of EP 2 510 096 by the European Patent Office
Business Wire - Tue Nov 04, 11:30AM CST
Regulatory News :
Cellectis: Event Report: Individual Shareholders' Meeting Held on October 23, 2014
Business Wire - Thu Oct 30, 1:00PM CDT
Regulatory News :
Cellectis: First-Half 2014 Financial Results
Business Wire - Tue Sep 30, 1:32PM CDT
--As of September 30, available cash stands at EUR103 million
Cellectis Plant Sciences Launches Its New Website
Business Wire - Mon Sep 29, 11:00AM CDT
Cellectis (Paris:ALCLS) plant sciences, the plant genome engineering company, is proud to announce today the launch of its new website www.cellectis-plantsciences.com.
Cellectis : Individual Shareholder Meeting
Business Wire - Tue Sep 23, 11:01AM CDT
Regulatory News :
Event report: Cellectis R&D/ Analyst Day
Business Wire - Tue Sep 16, 1:49PM CDT
Regulatory News:
Cellectis announces the closing of the sale of its Swedish subsidiary Cellectis AB to Takara Bio Inc.
Business Wire - Thu Sep 04, 12:30AM CDT
Regulatory News:
Cellectis: Genome Engineering & CART Cells: At the Forefront of Immuno-Oncology
Business Wire - Tue Sep 02, 11:31AM CDT
Regulatory News:
Pfizer's Stake in Cellectis' Capital is Welcomed by Its Shareholders
Business Wire - Thu Jul 31, 11:13AM CDT
--Cellectis SA on July 31, 2014
Cellectis divests off Swedish subsidiary for undisclosed sum to Takara Bio in Japan
M2 - Tue Jul 29, 6:24AM CDT
Cellectis SA (Paris:ALCLS.PA), a biopharmaceutical company focused on oncology, today announced the sale of its Swedish subsidiary Cellectis AB to the Japanese company Takara Bio Inc.
Not For The Faint Of CAR-T: The CAR-T Landscape In Early 2015
EP Vantage - Seeking Alpha - Fri Feb 06, 1:26PM CST
This is an extract from a longer report. If you followed last year's explosion of enthusiasm in CAR therapies you might have assumed that this was a super-novel approach that had just burst onto the scientific stage. In fact work on the synthetic...
BLUE: 90.70 (+0.93), CLRB: 2.45 (+0.28), BLCM: 20.00 (-0.81), KITE: 62.59 (+0.82), JUNO: 40.52 (+0.18), NVS: 102.20 (-0.17)
CAR-T Vs ErbB3 Market Opportunity Comparison
Decision Analytics - Seeking Alpha - Wed Jan 21, 12:32PM CST
CAR-T therapy, also known as "Adoptive Immunotherapy", has been the result of significant investor excitement recently. One look at the stock charts for JUNO and KITE is illustrative of this optimism. While this enthusiasm may be warranted,...
MACK: 10.22 (+0.40), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), BLCM: 20.00 (-0.81), KITE: 62.59 (+0.82), AVEO: 0.84 (-0.06), JUNO: 40.52 (+0.18), GSK: 47.94 (+1.99), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Kite Pharma/Amgen: A Strong Combination
Henry Wolfe - at Seeking Alpha - Thu Jan 15, 12:19PM CST
ZIOP: 9.64 (-0.35), BLCM: 20.00 (-0.81), KITE: 62.59 (+0.82), AMGN: 153.48 (+0.30), JUNO: 40.52 (+0.18)
Cellectis and Ohio State University, Through the Ohio State Innovation Foundation, Enter Into Licensing Agreement for Chimeric Antigen Receptor Technology Targeting Multiple Myeloma
Business Wire - Tue Jan 13, 12:30AM CST
Regulatory News:
Cellectis Plans to Conduct Registered Initial Public Offering in the U.S.
Business Wire - Thu Jan 08, 12:17PM CST
Regulatory News:
Cellectis Announces the Issuance by the USPTO of a Patent Covering a Seminal Nuclease-Based "gene editing" Method
Business Wire - Tue Jan 06, 11:30AM CST
Regulatory News:
Cellectis Is Late To The CAR-T Cell Race, But Could Finish First
Intrepid Investor - at Seeking Alpha - Fri Jan 02, 3:21PM CST
BLUE: 90.70 (+0.93), BLCM: 20.00 (-0.81), KITE: 62.59 (+0.82), JUNO: 40.52 (+0.18), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
Cellectis Plant Sciences and Two Blades Foundation Announce the Execution of a Cross-License Agreement on TAL Effector Nuclease Technologies
Business Wire - Thu Dec 18, 11:00AM CST
Regulatory News:
Cellectis Announces Upcoming Presentations at the 56th Annual Meeting of the American Society of Hematology (ASH)
Business Wire - Mon Nov 24, 11:19AM CST
Regulatory News :
Cellectis Received Proceeds of EUR13 Million Through the Exercise of Warrants
Business Wire - Wed Nov 12, 12:47PM CST
Regulatory News:
Cellectis: TALEN(TM) Technology: Grant of EP 2 510 096 by the European Patent Office
Business Wire - Tue Nov 04, 11:30AM CST
Regulatory News :
Cellectis: Event Report: Individual Shareholders' Meeting Held on October 23, 2014
Business Wire - Thu Oct 30, 1:00PM CDT
Regulatory News :
Cellectis: First-Half 2014 Financial Results
Business Wire - Tue Sep 30, 1:32PM CDT
--As of September 30, available cash stands at EUR103 million
Cellectis Plant Sciences Launches Its New Website
Business Wire - Mon Sep 29, 11:00AM CDT
Cellectis (Paris:ALCLS) plant sciences, the plant genome engineering company, is proud to announce today the launch of its new website www.cellectis-plantsciences.com.
Cellectis : Individual Shareholder Meeting
Business Wire - Tue Sep 23, 11:01AM CDT
Regulatory News :
Event report: Cellectis R&D/ Analyst Day
Business Wire - Tue Sep 16, 1:49PM CDT
Regulatory News:
Cellectis announces the closing of the sale of its Swedish subsidiary Cellectis AB to Takara Bio Inc.
Business Wire - Thu Sep 04, 12:30AM CDT
Regulatory News:
Cellectis: Genome Engineering & CART Cells: At the Forefront of Immuno-Oncology
Business Wire - Tue Sep 02, 11:31AM CDT
Regulatory News:
Pfizer's Stake in Cellectis' Capital is Welcomed by Its Shareholders
Business Wire - Thu Jul 31, 11:13AM CDT
--Cellectis SA on July 31, 2014
Cellectis divests off Swedish subsidiary for undisclosed sum to Takara Bio in Japan
M2 - Tue Jul 29, 6:24AM CDT
Cellectis SA (Paris:ALCLS.PA), a biopharmaceutical company focused on oncology, today announced the sale of its Swedish subsidiary Cellectis AB to the Japanese company Takara Bio Inc.
